Literature DB >> 34284049

Near-infrared light-responsive liposomes for protein delivery: Towards bleeding-free photothermally-assisted thrombolysis.

Ahmed Refaat1, Blanca Del Rosal2, Jathushan Palasubramaniam3, Geoffrey Pietersz4, Xiaowei Wang5, Simon E Moulton6, Karlheinz Peter7.   

Abstract

Smart drug delivery systems represent state-of-the-art approaches for targeted therapy of life-threatening diseases such as cancer and cardiovascular diseases. Stimuli-responsive on-demand release of therapeutic agents at the diseased site can significantly limit serious adverse effects. In this study, we engineered a near-infrared (NIR) light-responsive liposomal gold nanorod-containing platform for on-demand delivery of proteins using a hybrid formulation of ultrasmall gold nanorods (AuNRs), thermosensitive phospholipid (DPPC) and non-ionic surfactant (Brij58). In light-triggered release optimization studies, 55.6% (± 4.8) of a FITC-labelled model protein, ovalbumin (MW 45 kDa) was released in 15 min upon NIR irradiation (785 nm, 1.35 W/cm2 for 5 min). This platform was then utilized to test on-demand delivery of urokinase-plasminogen activator (uPA) for bleeding-free photothermally-assisted thrombolysis, where the photothermal effect of AuNRs would synergize with the released uPA in clot lysis. Urokinase light-responsive liposomes showed 80.7% (± 4.5) lysis of an in vitro halo-clot model in 30 min following NIR irradiation (785 nm, 1.35 W/cm2 for 5 min) compared to 36.3% (± 4.4) and 15.5% (± 5.5) clot lysis from equivalent free uPA and non-irradiated liposomes respectively. These results show the potential of low-dose, site-specific thrombolysis via the combination of light-triggered delivery/release of uPA from liposomes combined with photothermal thrombolytic effects from gold nanorods. In conclusion, newly engineered, gold nanorod-based, NIR light-responsive liposomes represent a promising drug delivery system for site-directed, photothermally-stimulated therapeutic protein release.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug release; Gold nanorods; Light-responsive liposomes; Photothermally-assisted thrombolysis; Urokinase liposomes; uPA

Year:  2021        PMID: 34284049     DOI: 10.1016/j.jconrel.2021.07.024

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

1.  Light-responsive biomaterials for ocular drug delivery.

Authors:  Hend A M Abdelmohsen; Nikki A Copeland; John G Hardy
Journal:  Drug Deliv Transl Res       Date:  2022-06-24       Impact factor: 4.617

Review 2.  Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis.

Authors:  Haikun Liu; Geoffrey Pietersz; Karlheinz Peter; Xiaowei Wang
Journal:  J Nanobiotechnology       Date:  2022-02-08       Impact factor: 10.435

3.  Magnet-Guided Bionic System with LIFU Responsiveness and Natural Thrombus Tropism for Enhanced Thrombus-Targeting Ability.

Authors:  Ni Fang; Jia Liu; Jingxin Hou; Yixin Zhong; Ying Luo; Liu Hu; Wenli Zhang; Junrui Wang; Jie Xu; Jun Zhou; Yu Zhang; Haitao Ran; Dajing Guo
Journal:  Int J Nanomedicine       Date:  2022-05-04

4.  Cyclic RGD functionalized PLGA nanoparticles loaded with noncovalent complex of indocyanine green with urokinase for synergistic thrombolysis.

Authors:  Sha Zhang; Jinjie Li; Jiefeng Ren; Zaiyao Xue; Xinlian Qi; Quanjin Si
Journal:  Front Bioeng Biotechnol       Date:  2022-08-10

Review 5.  Applications of phase change materials in smart drug delivery for cancer treatment.

Authors:  Jianfeng Bao; Hui Tu; Jing Li; Yijia Li; Shan Yu; Jingpi Gao; Kun Lei; Fengshou Zhang; Jinghua Li
Journal:  Front Bioeng Biotechnol       Date:  2022-09-12

6.  Thrombus-targeted nano-agents for NIR-II diagnostic fluorescence imaging-guided flap thromboembolism multi-model therapy.

Authors:  Zichen Cao; Xinyu Zhang; Zheng Wei; Chuanhui Song; Huihui Zou; Jianchuan Ran; Hongbo Zhang; Diya Xie; Shengwei Han; Yufeng Wang; Yu Cai; Wei Han
Journal:  J Nanobiotechnology       Date:  2022-10-14       Impact factor: 9.429

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.